Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for Cytokinetics (CYTK) over the last 12 years, with Dec 2024 value amounting to -$5.26.

  • Cytokinetics' EPS (Weighted Average and Diluted) fell 87.50% to -$2.55 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.29, marking a year-over-year decrease of 16.91%. This contributed to the annual value of -$5.26 for FY2024, which is 3.49% up from last year.
  • As of FY2024, Cytokinetics' EPS (Weighted Average and Diluted) stood at -$5.26, which was up 3.49% from -$5.45 recorded in FY2023.
  • In the past 5 years, Cytokinetics' EPS (Weighted Average and Diluted) registered a high of -$1.97 during FY2020, and its lowest value of -$5.45 during FY2023.
  • In the last 3 years, Cytokinetics' EPS (Weighted Average and Diluted) had a median value of -$5.26 in 2024 and averaged -$5.01.
  • Per our database at Business Quant, Cytokinetics' EPS (Weighted Average and Diluted) slumped by 54.64% in 2022 and then climbed by 3.49% in 2024.
  • Over the past 5 years, Cytokinetics' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.97 in 2020, then slumped by 42.13% to -$2.80 in 2021, then crashed by 54.64% to -$4.33 in 2022, then dropped by 25.87% to -$5.45 in 2023, then grew by 3.49% to -$5.26 in 2024.